WeightWatchers launches a GLP-1 Companion Program inside its app

WeightWatchers has introduced a GLP-1 Companion Program, a medication-tailored plan that sits inside its app and is presented as behavioral support to use alongside GLP-1 drugs rather than instead of them. The offering was announced in April 2025 ^[1].

The announcement takes the form of a blog post on the company's site titled "Welcome to the GLP-1 Companion Program." The post describes the offering as a "GLP-1 tailored plan," and the page is gated: "This article is for members," with a prompt to see plans and upgrade ^[1].

That gate is the main limit on what is publicly known. The page does not list a price for the GLP-1 program. It does not say whether a user must already have a prescription for a GLP-1 medication to join, or whether the plan is meant for people who are still considering the drugs. It does not describe the day-to-day content of the plan, how often members check in, or whether a dietitian, coach or clinician is involved. It also does not explain how the GLP-1 plan differs from WeightWatchers' other programs ^[1]. Those details sit behind the membership wall and have not been disclosed on the public page ^[1].

The page does show what the company is promoting around the program. A banner offers a discount on annual membership: "Kickstart your weight-loss journey now—save 50% on a 12-month plan!" ^[1]. The same page invites readers to sign up for a clinical newsletter that WeightWatchers describes as a way to follow new research, new treatments and misinformation in weight management. The newsletter form asks users to confirm they are 18 or older and to consent to receiving email from the company, which can be revoked at any time through an unsubscribe link ^[1].

WeightWatchers is not selling the medication through this page. The public description frames the product as a companion to GLP-1 treatment, not a source of it, and the public portion of the page contains no prescribing information, no dosing guidance and no drug-specific clinical advice ^[1]. The page also does not name specific medications. It does not mention semaglutide, sold as Ozempic, Wegovy and Rybelsus, or tirzepatide, sold as Mounjaro and Zepbound ^[1].

Why it matters for patients

A mainstream weight-loss company is now marketing a product built around medication use rather than only around food and activity tracking. The program's name refers to the drug class itself, which signals that WeightWatchers expects the medication audience to be a lasting part of its business rather than a side interest ^[1].

For patients, the practical problem is the information gap. Someone already taking a GLP-1 drug, or weighing whether to add a paid behavioral program to a medication routine, cannot currently compare this plan's price, format or staffing against alternatives using public information, because the details are reserved for members ^[1]. Whether the program requires a prescription, whether it coordinates with a prescriber, and whether it is included in an existing WeightWatchers membership have not been reported ^[1].

The announcement also does not address insurance. There is no public statement on whether any part of the program could be covered by a health plan or a flexible spending account, or whether it is a cash-pay product only ^[1].

What has not been disclosed, and what would matter most to a patient deciding, is what the plan actually asks members to do each week. Without that, the public description is limited to where the program lives — inside the WeightWatchers app — and the general claim that it is meant to accompany medication rather than replace it ^[1].